NR 565 / NR565 Advanced Pharmacology Fundamentals Week 1 Quiz bank | Chapters 2, 7, 8 | LATEST, Q & A | Chamberlain College
Chapter 8. An Introduction
... [Show More] to Pharmacogenomics
____ 1. Pharmacogenetic testing is required by the U.S. Food and Drug Administration prior to prescribing:
1. Erythromycin
2. Digoxin
3. Cetuximab
4. Rifampin
____ 2. Carbamazepine has a Black Box Warning recommending testing for the HLA-B*1502 allele in patients with Asian ancestry prior to starting therapy due to:
1. Decreased effectiveness of carbamazepine in treating seizures in Asian patients with the HLA-B*1502 allele
2. Increased risk for drug interactions in Asian patients with the HLA-B*1502 allele
3. Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-B*1502 allele
4. Patients who have the HLA-B*1502 allele being more likely to have a resistance to carbamazepine
____ 3. A genetic variation in how the metabolite of the cancer drug irinotecan SN-38 is inactivated by the body may lead to:
1. Decreased effectiveness of irinotecan in the treatment of cancer
2. Increased adverse drug reactions, such as neutropenia
3. Delayed metabolism of the prodrug irinotecan into the active metabolite SN-38
4. Increased concerns for irinotecan being carcinogenic
____ 4. Patients who have a poor metabolism phenotype will have:
1. Slowed metabolism of a prodrug into an active drug, leading to accumulation of prodrug
2. Accumulation of inactive metabolites of drugs
3. A need for increased dosages of medications
4. Increased elimination of an active drug
____ 5. Ultra-rapid metabolizers of drugs may have:
1. To have dosages of drugs adjusted downward to prevent drug accumulation
2. Active drug rapidly metabolized into inactive metabolites, leading to potential therapeutic failure
6. Increased elimination of active, nonmetabolized drug
4. Slowed metabolism of a prodrug into an active drug, leading to an accumulation of prodrug
____ 7. A provider may consider testing for CYP2D6 variants prior to starting tamoxifen for breast cancer to:
1. Ensure the patient will not have increased adverse drug reactions to the tamoxifen
2. Identify potential drug-drug interactions that may occur with tamoxifen
3. Reduce the likelihood of therapeutic failure with tamoxifen treatment
4. Identify poor metabolizers of tamoxifen
____ 8. Genetic polymorphisms account for differences in metabolism, including:
1. Poor metabolizers, who lack a working enzyme [Show Less]